BR112018077397A2 - diprovocims: uma classe de agonistas de tlr - Google Patents

diprovocims: uma classe de agonistas de tlr

Info

Publication number
BR112018077397A2
BR112018077397A2 BR112018077397A BR112018077397A BR112018077397A2 BR 112018077397 A2 BR112018077397 A2 BR 112018077397A2 BR 112018077397 A BR112018077397 A BR 112018077397A BR 112018077397 A BR112018077397 A BR 112018077397A BR 112018077397 A2 BR112018077397 A2 BR 112018077397A2
Authority
BR
Brazil
Prior art keywords
compound
diprovocin
diprovocim
tlr agonists
agonists
Prior art date
Application number
BR112018077397A
Other languages
English (en)
Inventor
Beutler Bruce
L Boger Dale
Original Assignee
Univ Texas
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Scripps Research Inst filed Critical Univ Texas
Publication of BR112018077397A2 publication Critical patent/BR112018077397A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

composto de diprovocim que corresponde, quanto à estrutura, à fórmula estrutural v, dentro do qual a, w, z, r1, r2, r3 e r4 (quando presente) são definidos. um composto de diprovocim tem propriedades de adjuvante imunológico em células humanas e de camundongo em cultura e na imunização in vivo de camundongos. uma composição que contém um diprovocim e um método para usar um composto também são revelados. a atividade imunoestimulante de um composto de diprovocim é similar à de lps, com o qual não tem nenhuma similaridade estrutural aparente. um composto contemplado não porta nenhuma similaridade estrutural com nenhum dos agonistas de lipoproteína tlr1/tlr2 nem com qualquer outro agonista de tlr sintético, e é notoriamente fácil de preparar e modificar sinteticamente.
BR112018077397A 2016-06-29 2017-06-29 diprovocims: uma classe de agonistas de tlr BR112018077397A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662356314P 2016-06-29 2016-06-29
PCT/US2017/040028 WO2018005812A1 (en) 2016-06-29 2017-06-29 Diprovocims: a new and potent class of tlr agonists

Publications (1)

Publication Number Publication Date
BR112018077397A2 true BR112018077397A2 (pt) 2019-10-01

Family

ID=60787607

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018077397A BR112018077397A2 (pt) 2016-06-29 2017-06-29 diprovocims: uma classe de agonistas de tlr

Country Status (10)

Country Link
US (1) US11040959B2 (pt)
EP (1) EP3445758B1 (pt)
JP (1) JP6964298B2 (pt)
KR (1) KR102522730B1 (pt)
CN (1) CN109641878B (pt)
AU (1) AU2017290238B2 (pt)
BR (1) BR112018077397A2 (pt)
CA (1) CA3026178C (pt)
IL (1) IL263388B (pt)
WO (1) WO2018005812A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3829571A4 (en) * 2018-08-02 2022-04-27 The Board Of Regents Of The University Of Texas System ADJUVANT ACTION OF THE TLR1/2 AGONIST DIPROVOCIM IN SYNERGY WITH CHECKPOINT INHIBITING ANTIBODIES TO COMBAT DISEASE
WO2021242923A1 (en) 2020-05-27 2021-12-02 Axial Therapeutics, Inc. Tlr2 modulator compounds, pharmaceutical compositions and uses thereof
WO2023212650A1 (en) * 2022-04-29 2023-11-02 The Scripps Research Institute Next generation diprovocims that activate the innate and adaptive immune response
WO2024064661A2 (en) * 2022-09-20 2024-03-28 The Curators Of The University Of Missouri Amino acid-modified lipids for rna delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE361068T1 (de) * 2001-08-08 2007-05-15 Pentraxin Therapeutics Ltd Wirkstoff zur entfernung einer unerwünschten proteinpopulation aus dem plasma
WO2005016235A2 (en) 2003-04-14 2005-02-24 The Regents Of The University Of California Combined use of impdh inhibitors with toll-like receptor agonists
PE20071079A1 (es) 2005-11-15 2007-12-16 Cytokinetics Inc Compuestos de piperidina como inhibidores de la proliferacion celular
JP5848748B2 (ja) 2010-03-23 2016-01-27 アイアールエム・リミテッド・ライアビリティ・カンパニーＩｒｍ，Ｌｌｃ 感染症、炎症、呼吸器疾患などの処置に使用するｔｌｒ２アゴニストとしての化合物（システインベースのリポペプチド）および組成物
CA2902342C (en) 2013-02-25 2017-10-17 The Scripps Research Institute Neoseptins: small molecule adjuvants
WO2016022700A2 (en) * 2014-08-06 2016-02-11 The Scripps Research Institute Tlr-independent small molecule adjuvants

Also Published As

Publication number Publication date
CA3026178C (en) 2024-05-21
KR20190014133A (ko) 2019-02-11
KR102522730B1 (ko) 2023-04-19
AU2017290238B2 (en) 2021-02-18
EP3445758B1 (en) 2020-11-04
EP3445758A1 (en) 2019-02-27
US20200207742A1 (en) 2020-07-02
WO2018005812A1 (en) 2018-01-04
US11040959B2 (en) 2021-06-22
EP3445758A4 (en) 2019-09-25
AU2017290238A1 (en) 2018-12-13
CN109641878B (zh) 2021-09-14
JP2019519574A (ja) 2019-07-11
JP6964298B2 (ja) 2021-11-10
CN109641878A (zh) 2019-04-16
IL263388A (en) 2018-12-31
CA3026178A1 (en) 2018-01-04
IL263388B (en) 2021-02-28

Similar Documents

Publication Publication Date Title
BR112018077397A2 (pt) diprovocims: uma classe de agonistas de tlr
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
BR112017002053A2 (pt) composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto
BR112014018679A2 (pt) variantes de albumina
BR112015019817A2 (pt) interface de vedação para um compartimento de telecomunicações
BR112018075947A2 (pt) composições de revestimento
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
BR112015017869A2 (pt) hidroalquilação aromtática de alquilo para a produção de plastificantes
BR112018010271A2 (pt) material cristalino sintético emm-28, sua preparação e uso
BR112017008176A2 (pt) método de preparação do carbonato de ácido glicérico.
BR112015017572A2 (pt) emulsão aquosa, uso da emulsão, método de fabricação da emulsão, método para operar um tomógrafo e método para detectar um composto semifluorado
CR20180503A (es) Composiciones y métodos para programar células terapéuticas utilizando nanoportadores de ácidos nucleicos dirigidos
BR112017028194A2 (pt) moduladores de diaciglicerol aciltransferase 2 (dgat2)
AR104174A1 (es) Oxadiazoles sustituidos con deuterio
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
BR112017012062A2 (pt) composição de revestimento aquosa e processo de preparar a mesma
BR112013014715B8 (pt) processo para produzir um artigo oco polimérico
BR112014032516A2 (pt) método e dispositivo para processamento de imagem
BR112013017520A2 (pt) composto bicíclico ou sal do mesmo
UY37016A (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
BR112016028639A2 (pt) composição de tintura de cabelo
BR112016010112A2 (pt) composição de adesivo
BR112018014239A2 (pt) métodos e composições para o tratamento de cabelos danificados
BR112018073690A2 (pt) formulação contendo agonista de tlr e métodos de uso
PE20091528A1 (es) Vacunas contra la malaria

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]